Review Article Open Access

The Effect of Pioglitazone Versus Metformin on Bone Minerals Density (BMD) in Patients with Type 2 Diabetic Mellitus

Abstract

Background: More than 9 million osteoporotic fractures are recorded annually worldwide. Osteoporosis is a significant contributor to morbidity and lost life years globally. A substantial number of studies examined the association between type 2 DM and fracture risk. The prevention of fractures is an important goal for studies concerning older adults. Aim: To assess the effect of pioglitazone and metformin on bone minerals density among the patients with diabetic mellitus type 2. Methodology: A comparative study was carried out from 06 December 2021 to 01 June 2022. A probability sample (50) was selected. The data were collected through the application of a validated questionnaire, in the parts, the first part was related to social and demographic data, and the second part was about medication and bone scan. Results: Most of patients were in age group (51-65) and constitute (48%) most of them were females (88%). The results show that (60%) of patients have severe obesity. This finding shows that the effect of pioglitazone on bone minerals density in patients with DM were high. Metformin shows moderate impact on bones minerals in DM patients and constitutes (38%) of total samples. Conclusion: The study concluded that the age group (51-65 years) is more prone to bone fractures and resorption of its density. BMI has an effect on bone, especially for patients with type 2 diabetes. Most of the samples were women, and their diagnosis of diabetes was known in less than 5 years.

Fadwa Ghassan*, Zainab Mohammed Abdulwahab

To read the full article Download Full Article